tbuckley/cabot-search huggingface dataset:
Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 Patients From the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group
Authors: A. Sureda, R. Arranz, A. Iriondo, E. Carreras, J.J. Lahuerta, J. García-Conde, I. Jarque, M.D. Caballero, C. Ferrà, A. López, J. García-Laraña, R. Cabrera, D. Carrera, M.D. Ruiz-Romero, A. León, J. Rifón, J. Díaz-Mediavilla, R. Mataix, M. Morey, J.M. Moraleda, A. Altés, A. López-Guillermo, J. de la Serna, J.M. Fernández-Rañada, J. Sierra, E. Conde
Journal: Journal of Clinical Oncology (2001)

PURPOSE: To analyze clinical outcome and significant prognostic factors for overall (OS) and time to treatment failure (TTF) in a group of 494 patients with Hodgkin’s disease (HD) undergoing autologous stem-cell transplantation (ASCT). PATIENTS AND METHODS: Detailed records from the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group Database on 494 HD patients who received an ASCT between January 1984 and May 1998 were reviewed. Two hundred ninety-eight males and 196 females with a median age of 27 years (range, 1 to 63 years) received autografts while in complete remission (n = 203) or when they had sensitive disease (n = 206) or resistant disease (n = 75) at a median time of 26 months (range, 4 to 259 months) after diagnosis. Most patients received high-dose chemotherapy without radiation for conditioning (n = 443). The graft consisted of bone marrow (n = 244) or peripheral blood (n = 250). RESULTS: The 100-day mortality rate was 9%. The 5-year actuarial TTF and OS rates were 45.0% (95% confidence interval [CI], 39.5% to 50.5%) and 54.5% (95% CI, 48.4% to 60.6%), respectively. In multivariate analysis, the presence of active disease at transplantation, transplantation before 1992, and two or more lines of therapy before transplantation were adverse prognostic factors for outcome. Sixteen patients developed a secondary malignancy (5-year cumulative incidence of 4.3%) after transplantation. Adjuvant radiotherapy before transplantation, the use of total-body irradiation (TBI) in the conditioning regimen, and age ≥ 40 years were found to be predictive factors for the development of second cancers after ASCT. CONCLUSION: ASCT achieves long-term disease-free survival in HD patients. Disease status before ASCT is the most important prognostic factor for final outcome; thus, transplantation should be considered in early stages of the disease. TBI must be avoided in the conditioning regimen because of a significantly higher rate of late complications, including secondary malignancies.
Report on Uninsured Tries to Reverse Myths
Authors: B Vastag
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Her2-Positive Early Breast Cancer in the Pre-Trastuzumab and Trastuzumab Eras: a Triple Positive Subgroup Analysis of a Multicenter Retrospective Study
Authors: L. Pizzuti, C. Natoli, T. Gamucci, D. Sergi, L. Di Lauro, L. Moscetti, L. Mentuccia, A. Vaccaro, P. Trenta, P. Seminara, I.G. Rapposelli, V. Sini, D. Santini, I. Sperduti, P. Marchetti, P. Vici
Journal: Annals of Oncology (2014)
Msh2-mediated mismatch repair and apoptosis cooperate with DNA polymerase proofreading to suppress spontaneous cancer in mice
Authors: Tina M. Albertson, Laura E. Hays, Robert E. Goldsby, Winfried Edelmann, Bradley D. Preston
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

4850 

DNA replication fidelity, cell-cycle checkpoints, and apoptotic signaling all contribute to faithful genetic transmission and the suppression of tumorigenesis. Studies in E.coli and S. cerevisiae show that mismatch repair (MMR) and DNA polymerase proofreading are primary determinants of DNA replication fidelity that cooperate to ensure faithful DNA synthesis. However, the functional relationship of these pathways in mammals and their impact on cancer development is not known. Using mouse models, we studied the cooperation of DNA polymerase proofreading and MMR on suppression of spontaneous mutations and cancer. Mice deficient in DNA polymerase delta proofreading ( Pold1D400A ; Goldsby et al. PNAS , 99:15560, 2002) and MMR ( Mlh1null or Msh2null ) were bred to generate double-mutant mice. Mice homozygous deficient for both DNA polymerase delta (Pol delta) proofreading and MMR were not viable. However, Pol delta proofreading haploinsufficiency accelerates the cancer mortality of homozygous Mlh1null mice. Mlh1null haploinsufficiency also accelerates the cancer mortality of homozygous PoldD400A mutant mice. Fluctuation assays done on murine embryonic fibroblasts (MEFs) showed that Pold1  D400A /+/ Mlh1null/null MEFs had an ∼40-fold increase in spontaneous mutation rate over the single mutants alone, and a ∼340-fold increase over wildtype. In contrast the Pold1D400A/D400A/Mlh1null/+ MEFs exhibited no increase in mutation rate over the single mutants despite the increase in cancer mortality. This shows that MMR cooperates with Pol delta proofreading to suppress spontaneous mutations and cancers in mice. To further analyze the nature of this cooperation we used an allele of Msh2 , Msh2G674A , which contains a point mutation in the ATPase domain that uncouples the mismatch repair function and apoptotic signaling function of MMR (Lin et al, Cancer Res . 64: 517, 2004). These mice are deficient in mismatch repair, but proficient in MMR-mediated apoptotic signaling. We compared the cancer mortality of the Pold1D400A/+/Msh2null/null with Pold1D400A/+/Msh2G674A/G674A mice and found that there was a significant decrease in survival (median survival = 66 and 98 days, respecitvely; p < 0.001). These data show that DNA polymerase delta proofreading cooperates with MMR to suppress mutations and spontaneous cancers in mice and suggests that cooperation involves both Msh2-mediated mismatch repair and apoptotic signaling.
Do depression and living alone decrease the likelihood of smoking cessation in patients admitted with exacerbations of COPD? A retrospective audit
Authors: Kerrie Aldridge, Toni Jordan
Journal: European Respiratory Journal (2014)

In the literature, evidence has been conflicting on whether depressed patients are less likely to quit smoking than their euthymic counterparts. Based on observation in a respiratory ward in a University Hospital, it was noted that smokers admitted with exacerbations of COPD seemed to have a higher prevalence of depression, and higher risk of living alone than ex-smokers admitted for the same reason.  To assess the significance of this observation, a retrospective audit of 213 patients over 7 months looked at smoking status, depression and living arrangements. Electronic discharge records were viewed to identify patients who had been admitted with exacerbations of COPD, and who continued to smoke, had depression or lived alone.  148/213 admissions (69%) were ex-smokers. Out of this group 26 were depressed (17%), close to the population average for depression. Significantly more smokers were suffering from depression (pl0.05), with 21 out of 65 smokers identified as having depression (32%). There was no significant association between smoking status and living alone, with 29/65 smokers (44%) and 58/148 ex-smokers (40%) living alone. All smokers received verbal smoking cessation advice, but there was a self-reported quit rate of only 11% at 2 month follow up. Depression status and living alone did not affect this.  These results demonstrate an increased likelihood of smoking in depressed patients, and this may mean that depressed patients require more intensive smoking cessation programmes to achieve similar results to their euthymic peers. Living alone does not appear to affect likelihood of smoking cessation.
Abstract 4121: Effect of Dark Chocolate on Coronary Vasomotion in Patients after Heart Transplantation
Authors: Andreas J Flammer, Frank Hermann, Isabella Sudano, Lukas Spieker, Matthias Hermann, Thomas F Luscher, Frank Ruschitzka, Georg Noll, Roberto Corti
Journal: Circulation (2006)

Introduction: Patients after heart transplantation (HTPL) have endothelial dysfunction, increased platelet activation and show accelerated coronary atherosclerosis. Traditional risk factors, high o...
Prescribing antibiotics for sore throats
Authors: M. Lindbaek
Journal: BMJ (1999)

EDITOR—I found Butler et al's article interesting.1 In Norway problems with resistant bacteria are few and have been stable for 10 years. Important reasons for this may be the low total prescriptions for antibiotics and the high proportion of penicillin V prescribed. Prescriptions for antibiotics have decreased by 10% since 1993. One of …
Trabectedin (Tr) as single agent for advanced soft tissue sarcomas (STS) failing standard of care: Interim analysis of 1,400 patients (pts) in an expanded access program study.
Authors: B. L. Samuels, W. D. Tap, S. Patel, M. von Mehren, J. T. Hamm, P. E. Kaiser, S. Schuetze, J. Li, E. Bayever, G. D. Demetri
Journal: Journal of Clinical Oncology (2010)

10027 Background: Between 2005 and 2009, 1404 pts with advanced STS were enrolled in an Expanded Access Program (EAP) of Tr in the United States, Canada and Israel, and were treated with Tr 1.5mg/m2/ via 24h continuous IV infusion q21d. The purpose of this analysis was to assess activity and tolerability of Tr in pts treated in this EAP. Methods: A total of 25 centers participated, enrolling pts with incurable STS following failure of currently available therapies. Inclusion criteria were similar to Study ET743-STS-201 (J Clin Oncol, 2009 Sep 1;27(25):4188- 96). No restrictions were placed on the number of lines of prior therapy. Data cutoff for this analysis was September 28, 2009. Results: In this analysis of 1404 Tr-treated pts; 93% were enrolled in the US. Median age was 54 years (range16-87), 59% female; major histological subgroups were leiomyosarcoma (35%) and liposarcoma (15%). The majority of pts had prior treatment with an anthracycline and ifosfamide. Median number of Tr cycles administered was 3 (range 1-55); ≥6 cycles were given to 419 pts (30%). Median dose intensity of Tr was 1.3 mg/m2/cycle (0.20-1.77), 0.433 mg/m2/week (0.07; 0.59), relative dose intensity 87% (13-118). There were 429 (31%) dose reductions due to AE and 378 (27%) cycle delays. The most common AEs were neutropenia and transaminase elevations, however these were manageable and without serious clinical consequences. The primary reported causes of treatment termination (1191 pts) were disease progression (859 pts, 61%), adverse events (105, 7%), subject choice (99, 7%), and death (61, 4%) {fatal outcomes reported in association with adverse events 30; drug related, progressive disease 27, or other 4}. Reported best outcomes in 504 evaluable pts were CR 1 (<1%), PR 36 (7%), SD 166 (33%), PD 229 (45%). Conclusions: This EAP for heavily pretreated pts with STS represents one of the largest therapeutic experiences. Tr activity is consistent with prior trials, with a clinical benefit (objective responses + SD) of 41% with an expected toxicity profile. These results demonstrate the potential clinical utility of Tr in STS following failure of conventional therapies. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Johnson & Johnson Amgen, ARIAD, ArQule, Daiichi Sankyo, Genentech, Infinity, Johnson & Johnson, Novartis, Pfizer, PharmaMar, ZIOPHARM Oncology Johnson & Johnson Novartis, Pfizer, PharmaMar Amgen, ARIAD, ArQule, Daiichi Sankyo, Genentech, Infinity, Johnson & Johnson, Novartis, Pfizer, PharmaMar, ZIOPHARM Oncology ARIAD, ArQule, Daiichi-Sankyo, Infinity, Johnson & Johnson, PharmaMar
Value of Peptide Receptor Scintigraphy Using <sup>123</sup>I-Vasoactive Intestinal Peptide and <sup>111</sup>In-DTPA-D-Phe1-Octreotide in 194 Carcinoid Patients: Vienna University Experience, 1993 to 1998
Authors: Markus Raderer, Amir Kurtaran, Maria Leimer, Peter Angelberger, Bruno Niederle, Heinrich Vierhapper, Friedrich Vorbeck, Michael H. L. Hejna, Werner Scheithauer, Johann Pidlich, Irene Virgolini
Journal: Journal of Clinical Oncology (2000)

PURPOSE: To report our experience with both 123 I-vasoactive intestinal peptide (VIP) and 111 In-DTPA-D-Phe 1 -octreotide for imaging to identify primary and metastatic tumor sites in carcinoid patients. PATIENTS AND METHODS: One hundred ninety-four patients with a verified or clinically suspected diagnosis of a carcinoid tumor were injected with 111 In-DTPA-D-Phe 1 -OCT for imaging purposes, while 133 patients underwent scanning with both 123 I-VIP and 111 In-DTPA-D-Phe 1 -OCT in random order. Imaging results were compared with computed tomography scans, results of conventional ultrasound, endosonography, and endoscopy, and results of surgical exploration in case of inconclusive conventional imaging. RESULTS: Primary or recurrent carcinoid tumors could be visualized with 111 In-DTPA-D-Phe 1 -OCT in 95 (91%) of 104 patients; metastatic sites were identified in 110 (95%) of 116 patients. In 11 (51%) of 21 patients with suggestive symptoms but without identified lesions by conventional imaging, focal tracer uptake located the carcinoid tumor. In addition, metastatic disease was demonstrated in three patients after resection. In a direct comparison in the 133 patients who underwent both imaging modalities, 111 In-DTPA-D-Phe 1 -OCT was found to be superior to 123 I-VIP, with 35 (93%) of 38 versus 32 (82%) of 38 scans being positive in primary or recurrent tumors, 58 (90%) of 65 versus 53 (82%) of 65 being positive in patients with metastatic sites, and seven (44%) of 16 versus four (25%) of 16 being positive in patients with symptoms but otherwise negative work-ups. Overall, additional lesions not seen on conventional imaging were imaged in 43 (41%) of 158 versus 25 (25%) of 103 scans with 111 In-DTPA-D-Phe 1 -OCT and 123 I-VIP, respectively. CONCLUSION: Both peptide tracers have a high sensitivity for localizing tumor sites in patients with ascertained or suspected carcinoid tumors, with 111 In-DTPA-D-Phe 1 -OCT scintigraphy being more sensitive than 123 I-VIP receptor scanning. Both, however, had a higher diagnostic yield than conventional imaging, as verified by surgical intervention or long-term follow-up. The combination of both peptide receptor scans does not seem to further enhance diagnostic information.
Antigenic Relationship Between Mycobacterium bovis (BCG) and a Guinea Pig Hepatoma
Authors: Tibor Borsos, Herbert J. Rapp
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Antigenic Relationship Between Mycobacterium bovis (BCG) and a Guinea Pig Hepatoma Get access Tibor Borsos, Tibor Borsos Search for other works by this author on: Oxford Academic PubMed Google Scholar Herbert J. Rapp Herbert J. Rapp Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 51, Issue 3, September 1973, Pages 1085–1086, https://doi.org/10.1093/jnci/51.3.1085 Published: 01 September 1973 Article history Received: 25 May 1973 Accepted: 18 June 1973 Published: 01 September 1973
Impaired skin wound healing in lumican-null mice
Authors: J-T. Yeh, L-K. Yeh, S-M. Jung, T-J. Chang, H-H. Wu, T-F. Shiu, C-Y. Liu, W.W-Y. Kao, P-H. Chu
Journal: British Journal of Dermatology (2010)

Previous studies have demonstrated that the lack of lumican delayed corneal wound healing in lumican-null (Lum(-/-) ) mice. This defect is rescued by the addition of glycosylated lumican core protein to the injured corneas.We examined the hypothesis that lumican is also required for the healing of cutaneous wounds using Lum(-/-) mice.We demonstrated the basic thinner skin phenotypes in Lum(-/-) mice at different time points and the changes in arrangement of collagen fibres by transmission electron microscopy (TEM). A full skin thickness wound was generated by punch biopsy (6 mm diameter) in experimental Lum(-/-) and wild-type mice. The closure of injured skin was measured after various periods of time (3, 6, 12, 18 days). Specimens of injured and uninjured skin (serving as control) were then subjected to morphological examination with haematoxylin and eosin and Masson trichrome stains, and by TEM. Immunohistochemical staining with anti-CD68 antibody was used to assess the presence of macrophages in injured skin healing for various periods of time. Semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) was used to elucidate the transforming growth factor (TGF)-β1-induced myofibroblast phenotypic genes.Skin of adult Lum(-/-) mice (3 months and older) was much thinner (40% less) than that of age-matched wild-type mice. This phenomenon was aggravated in older mice. TEM revealed disoriented and irregular collagen fibrils in the dermis of Lum(-/-) mice. Delayed wound healing with an increase in inflammatory macrophages was compatible with the delayed response of the expression of TGF-β1, type I collagen α1 and fibronectin at the mRNA level by semiquantitative RT-PCR in the Lum(-/-) mice.Our data demonstrate that lumican plays pivotal roles in skin collagen fibrillogenesis and wound healing.
A Sense of Proportion: The Place of Psychiatry in Medicine
Authors: G G Lloyd
Journal: Journal of the Royal Society of Medicine (1996)

Psychiatric disorders have a high prevalence in medical and surgical patients and the need for an effective liaison psychiatry service is widely accepted. However, the development of liaison psychiatry may be jeopardised by the trend towards establishing psychiatric facilities in the community rather than in hospitals. Alternative methods of funding may need to be established if the future of liaison psychiatry is to be safeguarded.
Abstract 3698: Hyperactive AKT pathway and reactivation of the MAPK/ERK pathway in melanoma cells resistant to dual BRAF and MEK inhibition
Authors: Victoria E. Wang, Frank McCormick, Jeffrey Settleman
Journal: Cancer Research (2014)

Abstract In order to understand the mechanisms of resistance in melanoma cells treated with dual BRAF and MEK inhibitors, A375 and SK-Mel-28 cell lines, both harboring the BRAF V600E mutation, were treated with escalating doses of vemurafenib and cobimetinib to generate dual resistant lines. Resulting cells demonstrated 10 to 30 fold increase in resistance to the drug combination compared with the parental lines. The resistance phenotype could not be reversed by an ERK inhibitor. RNA sequencing and Western analyses revealed hyperactivation of the PI3K-AKT pathway in the A375 dual resistant cells. These cells may be re-sensitized with either a pan-PI3K inhibitor or PI3K/mTOR inhibitor. The SK-Mel-28 cells have constitutively active PI3K/AKT pathways at baseline and thus demonstrate reactivation of the MAP/ERK pathway in dual resistant cells. The therapeutic implications of these findings will be discussed. Citation Format: Victoria E. Wang, Frank McCormick, Jeffrey Settleman. Hyperactive AKT pathway and reactivation of the MAPK/ERK pathway in melanoma cells resistant to dual BRAF and MEK inhibition. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3698. doi:10.1158/1538-7445.AM2014-3698
Goblet Cell Degranulation after Antigen Challenge in Sensitized Guinea Pigs
Authors: CARLOS AGUSTI, KIYOSHI TAKEYAMA, LARS OLAF CARDELL, IRIS UEKI, JAMES LAUSIER, YA-PING LOU, JAY A. NADEL
Journal: American Journal of Respiratory and Critical Care Medicine (1998)

Mucus hypersecretion is a common characteristic of asthma. Acute severe asthma is often associated with neutrophilic infiltration into airways. Neutrophils contain elastase, a potent secretagogue in airways. Therefore, we hypothesized that instillation of ovalbumin in sensitized guinea pigs causes goblet cell secretion by releasing elastase from recruited neutrophils. When we instilled ovalbumin into the trachea of ovalbumin-sensitized guinea pigs, early recruitment of neutrophils identified by 3,3'- diaminobenzidine staining, and goblet cell degranulation measured with a semiautomatic computer-based imaging system occurred. The Leumedin NPC 15669 (a drug that inhibits leukocyte recruitment) and an antibody to intercellular adhesion molecule-1 (ICAM-1) both prevented neutrophil recruitment and goblet cell degranulation, implicating leukocytes in the response. Using immunofluorescence we showed that the leukocytes recruited early after antigen challenge were CD-16-positive, implicating neutrophils. Pretreatment with the selective neutrophil elastase inhibitor ICI 200,355 also prevented ovalbumin-induced goblet cell degranulation, implicating elastase. We conclude that ovalbumin-induced goblet cell degranulation is due to neutrophil recruitment and elastase release.